Purpose A novel dissolution dynamic nuclear polarization (dDNP) polarizer platform is presented. The polarizer meets a number of key requirements for in vitro, preclinical, and clinical applications. Method It uses no liquid cryogens, operates in continuous mode, accommodates a wide range of sample sizes up to and including those required for human studies, and is fully automated. Results It offers a wide operational window both in terms of magnetic field, up to 10.1 T, and temperature, from room temperature down to 1.3 K. The polarizer delivers a 13C liquid state polarization for [1‐13C]pyruvate of 70%. The build‐up time constant in the solid state is approximately 1200 s (20 minutes), allowing a sample throughput of at least one sample per hour including sample loading and dissolution. Conclusion We confirm the previously reported strong field dependence in the range 3.35 to 6.7 T, but see no further increase in polarization when increasing the magnetic field strength to 10.1 T for [1‐13C]pyruvate and trityl. Using a custom dry magnet, cold head and recondensing, closed‐cycle cooling system, combined with a modular DNP probe, and automation and fluid handling systems, we have designed a unique dDNP system with unrivalled flexibility and performance.

No abstract

Abstract--The CPS Accel is a commercial PET camera based on a block detector with 64 LSO scintillator crystals (each 6.75 x 6.75 x 25 mm) read out with 4 photomultiplier tubes. The excellent timing resolution of LSO suggests that this camera might be used for time-of-flight (TOF) PET, thereby reducing the statistical noise significantly. Although the Accel achieves 3 ns coincidence resolution (a factor of two better than BGObased PET cameras), its timing resolution is nearly an order of magnitude worse than that demonstrated with individual LSO crystals. This paper quantifies the effect on the timing of each component in the Accel timing chain to identify which components most limit the camera's timing resolution. The components in the timing chain are: the scintillator crystal, the photomultiplier tube (PMT), the constant fraction discriminator (CFD), and the time to digital converter (TDC). To measure the contribution of each component, we construct a single crystal test system with high-performance versions of these components. This system achieves 221 ps fwhm coincidence timing resolution, which is used as a baseline measurement. One of the high-performance components is replaced by a production component, the coincidence timing resolution is remeasured, and the difference between measurements is the contribution of that (production) component. We find that the contributions of the TDC, CFD, PMT, and scintillator are 2000 ps, 1354 ps, 422 ps, and 326 ps fwhm respectively, and that the overall timing resolution scales like the square root of the amount of scintillation light detected by the PMT. Based on these measurements we predict that the limit for the coincidence timing resolution in a practical, commercial, LSO-based PET camera is 528 ps fwhm.

Positron Emission Tomography (PET) images are prone to motion artefacts due to the long acquisition time of PET measurements. Recently, simultaneous magnetic resonance imaging (MRI) and PET have become available in the first generation of Hybrid MR-PET scanners. In this work, the elimination of artefacts due to head motion in PET neuroimages is achieved by a new approach utilising MR-based motion tracking in combination with PET list mode data motion correction for simultaneous MR-PET acquisitions. The method comprises accurate MR-based motion measurements, an intra-frame motion minimising and reconstruction time reducing temporal framing algorithm, and a list mode based PET reconstruction which utilises the Ordinary Poisson Algorithm and avoids axial and transaxial compression. Compared to images uncorrected for motion, an increased image quality is shown in phantom as well as in vivo images. In vivo motion corrected images show an evident increase of contrast at the basal ganglia and a good visibility of uptake in tiny structures such as superior colliculi.

Contrast agents have been widely used in medicine to enhance contrast in magnetic resonance imaging (MRI). Among them, super paramagnetic iron oxide nanoparticles (SPION) have been reported to have low risk in clinical use. In our study, F127-Folate coated SPION was fabricated in order to efficiently target tumors and provide imaging contrast in MRI. SPION alone have an average core size of 15 nm. After stabilizing with Pluronic F127, the nanoparticles reached a hydrodynamic size of 180 nm and dispersed well in various kinds of media. The F127-Folate coated SPION were shown to specifically target folate receptor expressing cancer cells by flow cytometry analysis, confocal laser scanning microscope, as well as in vitro MRI. Furthermore, in vivo MRI images have shown the enhanced negative contrast from the F127-Folate coated SPION in tumor-bearing mice. In conclusion, our F127-Folate coated SPION have shown great potential as a contrast agent in MRI, as well as in the combination with drug delivery for cancer therapy.